Familial adenomatous polyposis-associated stage IIIB colon cancer with ultrahigh tumor mutational burden and POLE p.P286R mutation: a case report

Background Pathogenic POLE proofreading-domain variants can accompany ultrahigh tumor mutational burden (TMB) in microsatellite-stable (MSS) colorectal cancer. Their role in postoperative treatment of familial adenomatous polyposis (FAP)-associated cancer remains uncertain. Case summary A man in his early forties with extensive colorectal polyposis underwent subtotal colectomy for pT3N1b, clinically M0, stage IIIB ascending colon adenocarcinoma. Paired tumor–blood sequencing identified pathogenic germline APC p.R232*, tumor POLE p.P286R (variant allele fraction 19.75%; not detected in blood), MSS status, and panel-derived TMB of 333.57 mutations/Mb. Initial MMR immunohistochemistry was reported as pan-loss; repeat staining was interpreted as proficient MMR. Incomplete documentation of internal controls prevents confirmation of the cause of this discordance. After declining chemotherapy, the patient received five postoperative doses of sintilimab from February 14 to May 15, 2025. CEA had normalized before the first dose; CA72–4 had also declined after surgery. No recurrence was reported on available surveillance through September 14, 2026. Conclusion The case illustrates the value and limitations of integrated pathological and molecular assessment in FAP-associated cancer. The absence of measurable disease at treatment initiation, postoperative marker decline, and limited follow-up prevent attribution of the outcome to sintilimab. This observation cannot establish cure or the efficacy of adjuvant PD-1 monotherapy.

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2026-11-12
DOI
https://doi.org/10.3389/fonc.2026.1912024
Primary Topic
Genetic factors in colorectal cancer
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Familial adenomatous polyposis-associated stage IIIB colon cancer with ultrahigh tumor mutational burden and POLE p.P286R mutation: a case report

Wenyu Wu, Dongxin Tang, Huibin Chen, Haibo Cai
Frontiers in Oncology
Genetic factors in colorectal cancer
article

Familial adenomatous polyposis-associated stage IIIB colon cancer with ultrahigh tumor mutational burden and POLE p.P286R mutation: a case report

Wenyu Wu, Dongxin Tang, Huibin Chen, Haibo Cai
article en

Abstract

Background Pathogenic POLE proofreading-domain variants can accompany ultrahigh tumor mutational burden (TMB) in microsatellite-stable (MSS) colorectal cancer. Their role in postoperative treatment of familial adenomatous polyposis (FAP)-associated cancer remains uncertain. Case summary A man in his early forties with extensive colorectal polyposis underwent subtotal colectomy for pT3N1b, clinically M0, stage IIIB ascending colon adenocarcinoma. Paired tumor–blood sequencing identified pathogenic germline APC p.R232*, tumor POLE p.P286R (variant allele fraction 19.75%; not detected in blood), MSS status, and panel-derived TMB of 333.57 mutations/Mb. Initial MMR immunohistochemistry was reported as pan-loss; repeat staining was interpreted as proficient MMR. Incomplete documentation of internal controls prevents confirmation of the cause of this discordance. After declining chemotherapy, the patient received five postoperative doses of sintilimab from February 14 to May 15, 2025. CEA had normalized before the first dose; CA72–4 had also declined after surgery. No recurrence was reported on available surveillance through September 14, 2026. Conclusion The case illustrates the value and limitations of integrated pathological and molecular assessment in FAP-associated cancer. The absence of measurable disease at treatment initiation, postoperative marker decline, and limited follow-up prevent attribution of the outcome to sintilimab. This observation cannot establish cure or the efficacy of adjuvant PD-1 monotherapy.

Frontiers in OncologyVol. 16
Guizhou University (CN), Zunyi Medical University (CN)
Good health and well-being
Genetic factors in colorectal cancer
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon